Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $260,752.11 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 16,619 shares of the firm’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total transaction of $260,752.11. Following the transaction, the insider now directly owns 206,750 shares in the company, valued at approximately $3,243,907.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Centessa Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ:CNTA opened at $15.79 on Friday. The business’s 50-day moving average is $13.01 and its 200 day moving average is $10.84. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. Centessa Pharmaceuticals plc has a 1 year low of $5.15 and a 1 year high of $17.59. The firm has a market capitalization of $1.59 billion, a P/E ratio of -11.12 and a beta of 1.44.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, research analysts predict that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

CNTA has been the topic of several research reports. Oppenheimer reissued an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. BMO Capital Markets boosted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Guggenheim raised their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Jefferies Financial Group boosted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, B. Riley started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $25.17.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $48,000. Sandia Investment Management LP purchased a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at about $90,000. Fred Alger Management LLC acquired a new position in shares of Centessa Pharmaceuticals in the second quarter valued at about $99,000. EntryPoint Capital LLC acquired a new position in shares of Centessa Pharmaceuticals in the first quarter valued at about $109,000. Finally, Trexquant Investment LP acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth about $114,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.